|
ImmunoGen receives 30M dollars on license amendments with Sanofi
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer announced that the Company and an affiliate of Sanofi have amended their license agreements...
|
|
OBI Pharma to develop OBI-3424 a potential treatment of cancers expressing AKR1C3
OBI Pharma announced an agreement with Threshold Pharmaceuticals, Inc. to acquire TH3424, a first-in-class novel small-molecule prodrug...
|
|